Skip to main content
. Author manuscript; available in PMC: 2013 Aug 27.
Published in final edited form as: Immunity. 2011 Oct 28;35(4):550–561. doi: 10.1016/j.immuni.2011.09.012

Figure 5. GM-CSF Is Required for Tolerance by Inducing Prosurvival Genes in Graft Derived DCs.

Figure 5

(A) Recombinant GM-CSF (50 μl; 800 ng/ml) was injected locally in the graft during the first week after grafting (days 1, 3, 5, and 7) to mice that received either B6 (syngeneic) or F1 (rejecting) skin graft.

(B) GM-CSF (50 μl anti-GMSCF; 10 μg/ml) was blocked locally in syngeneic and tolerized mice at days 1, 3, 5, and 7 and graft survival monitored.

(C) WT or Csf2−/− mice were grafted with syngeneic (B6) or allogeneic (F1) skins and/or tolerized with αCD40L plus DST. Graft rejection was followed for 60 days after grafting.

(D) Graft-derived DCs were purified by sorting and analyzed for genes involved in apoptosis and survival by RT-PCR. For clarity labeling shows which major pathway of apoptosis is affected, and whether the gene is pro- or antiapoptotic. Shown is one of two experiments with similar results.